Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Bajaj Finance lowers deposit rates on certain tenures
It also lowered rates more on long-tenure deposits, perhaps indicating both the receivable time-lines of Bajaj Finance’s assets and stiffer competition for shorter-tenure commitments in